Consensus U.S. Physical Therapy, Inc.

Equities

USPH

US90337L1089

Market Closed - Nyse 04:00:02 2024-04-26 pm EDT 5-day change 1st Jan Change
100.6 USD +0.23% Intraday chart for U.S. Physical Therapy, Inc. +1.53% +8.02%

Evolution of the average Target Price on U.S. Physical Therapy, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d66e40a6a1.SdGgUbK8GHO89JCne-3znsj0adyzvKawsg3EcnSyUmc.fLr1YN7qXTnOsvP9GpuU9oSHPI-K0cGDw1iPNDH9MS8ui-kA29hyEvjC8w~772429a7b23106befe5bffa814485380
JPMorgan Adjusts U.S. Physical Therapy's Price Target to $117 From $99, Reiterates Overweight Rating MT
Barrington Ups Price Target on U.S. Physical Therapy to $122 From $120 After Strong Q4 Beat, Keeps Outperform Rating MT
Barrington Adjusts Price Target on U.S. Physical Therapy to $120 From $111, Maintains Outperform Rating MT
JPMorgan Adjusts Price Target on U.S. Physical Therapy to $99 From $108, Maintains Overweight Rating MT
Barrington Cuts Price Target on U.S. Physical Therapy to $111 From $124 on 'Tough Stock Market Environment', Reiterates Outperform Rating MT
JPMorgan Starts US Physical Therapy at Overweight With $108 Price Target MT
CJS Securities Upgrades US Physical Therapy to Market Outperform From Market Perform, $120 Price Target MT
Jefferies Adjusts U.S. Physical Therapy Price Target to $130 From $145, Maintains Buy Rating MT
Barrington Boosts Price Target on U.S. Physical Therapy to $124 From $116, Keeps Outperform Rating MT
BofA Securities Initiates U.S. Physical Therapy With Buy Rating, $138 Price Target MT
Barrington Research Adjusts Price Target on U.S. Physical Therapy to $110 From $107, Maintains Outperform Rating MT
Barrington Research Lowers U.S. Physical Therapy's Price Target to $107 From $123, Maintains Outperform Rating MT
Barrington Research Trims US Physical Therapy's Price Target to $123 From $144, Maintains Outperform Rating MT
Barrington Adjusts Price Target on US Physical Therapy to $144 From $142, Maintains Outperform Rating MT
CJS Securities Upgrades U.S. Physical Therapy to Outperform From Market Perform, Lower Price Target to $120 From $126 MT
Barrington Adjusts Price Target on US Physical Therapy to $142 From $139 on Long-Term Confidence, Maintains Outperform Rating MT
Sidoti Upgrades U.S. Physical Therapy to Buy From Neutral, Keeps $124 Price Target MT
U S PHYSICAL THERAPY : Barrington Adjusts Price Target on U.S. Physical Therapy to $139 From $130 After 'Exceptionally Strong Q2', Maintains Outperform Rating MT
U S PHYSICAL THERAPY : Barrington Research Upgrades U.S. Physical Therapy to Outperform From Market Perform, $130 Price Target MT
U S PHYSICAL THERAPY : Barrington Research Downgrades US Physical Therapy to Market Perform From Outperform; Removes $116 Price Target MT
U S PHYSICAL THERAPY : Barrington Research Adjusts Price Target on US Physical Therapy to $116 From $100, Keeps Outperform Rating MT
U.S. Physical Therapy, Inc. Provides Tax Rate Guidance for the Year 2017 and 2018 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
100.6 USD
Average target price
119.3 USD
Spread / Average Target
+18.58%
High Price Target
122.5 USD
Spread / Highest target
+21.76%
Low Price Target
115 USD
Spread / Lowest Target
+14.30%

Consensus detail

Consensus revision (last 18 months)

Analysts covering U.S. Physical Therapy, Inc.

JPMorgan Chase
Barrington Research
CJS Securities
Jefferies & Co.
BofA Securities
Sidoti & Co.
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock Market
  2. Equities
  3. USPH Stock
  4. Consensus U.S. Physical Therapy, Inc.